YK11 – Highly Powerful SARM that changes your Genetic Muscle-Building Potential

Selective Androgen Receptor Modulators (SARMs) are highly popular in the bodybuilding world because they provide muscle-gain and fat-loss results similar to anabolic-androgenic steroids (AAS), only without the same level of harsh side effects (i.e. HPTA shutdown, high blood pressure, liver problems). SARMs can do this because, unlike AAS, they are more selective when activating androgen receptors to produce muscle gains and fat loss.

Of course, like anabolic steroids, some SARMs are far more effective than others. And YK11 – one of the newest SARMs on the market – definitely fits into the upper-echelon of these compounds. In fact, YK11 has been proven to change your genetic potential for building muscle! This being said, let’s discuss how YK11 accomplishes this as well as why it might be the most powerful SARM available.

This powerful SARM can be purchased from RUI-Products.com, albeit for research purposes only.

YK11: both a Potent Androgen and Myostatin Inhibitor

So what makes YK11 so special, other than its value as a powerful SARM? You see, in addition to being a SARM and acting as a potent androgen with minimal adverse side effects, YK11 also acts as an effective myostatin inhibitor!

Myostatin is a protein that, when present, limits the growth and production of muscle tissue. By inhibiting myostatin, you can literally increase your genetic potential to build muscle tissue! Sounds almost too good to be true, but it is not only true but scientifically proven (1)!

Japanese researchers at Toho University further studied YK11’s role as a myostatin inhibitor (2). The scientists wanted to know why YK11 was so much more anabolic than other SARMs, so they deactivated follistatin (a naturally occurring myostatin inhibitor).Once the researchers did this, YK11 lost a significant amount of its anabolic properties. This proved that, in addition to acting as an androgen and an anabolic via androgenic pathways, YK11 also acted as a truly effective myostatin inhibitor, significantly boosting its anabolic effects!

This powerful SARM can be purchased from RUI-Products.com, albeit for research purposes only.

More Anabolic than DHT, without the Side Effects

Studies have shown YK11 to be significantly more anabolic & androgenic than the steroid dihydrotestosterone (DHT) – WITHOUT the adverse side effects of DHT, such as hair loss and prostate enlargement (3). In fact, with YK11, the prostate appears unaffected, and your hair actually grows!

YK11 truly does have the potential to revolutionize not only SARMs but anabolics in general. Its dual mechanism of action and anabolism via dual pathways makes it a truly unique, one-of-a-kind compound. And it has the potential to literally increase the genetic potential for building muscle while acting as an anabolic that will effectively build muscle at the same time – and all this with an excellent safety profile!

Assuming you’re looking to experience the incredible anabolic effects of YK11 in your research, you only have to dose subjects with 5-10mg/day. And given all the benefits we’ve discussed so far, it’s definitely worth giving YK11 a try.

> > Place your secure order at RUI-Products.com <<

Yours in sport,

George Spellwin

References
1. Biol Pharm Bull. 2011;34(3):318-23.(17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Kanno Y1, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye.
2. Biol Pharm Bull. 2013;36(9):1460-5.Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Kanno Y1, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y.
3. The effects of a myostatin inhibitor on lean body mass, strength, and power in resistance-trained males. Matthew Sharp, Ryan P Lowery, Kevin Shields, Jacob Ormes, Sean A McCleary, Jacob Rauch, Jeremy Silva, Ned Arick and Jacob M Wilson**Corresponding Author: Jacob M Wilson The University of Tampa, Tampa, Florida, USA.